Ischemic
stroke is a common condition with high morbidity and mortality, causing
irreversible neuronal damage and seriously affecting neurological
function. There has been no ideal effective treatment so far. The NX210
peptide is derived from the thrombospondin type 1 repeat (TSR) sequence
of SCO-spondin, and has been reported to exert various neurogenic
properties. This study investigated whether NX210 had therapeutic
effects and possible underlying mechanisms against cerebral
ischemia/reperfusion (I/R). Therefore, primary embryonic rat cortical
neurons and Sprague–Dawley (SD) rats that were subjected to
oxygen-glucose deprivation/reoxygenation (OGD/R) and middle cerebral
artery occlusion/reperfusion (MCAO/R) injuries, respectively, were
treated with or without NX210. We found that NX210 reduced OGD/R-induced
cell viability loss and cytotoxicity. NX210 decreased cerebral infarct
volume and brain edema, ameliorated neurological dysfunction, attenuated
oxidative stress damage, and diminished neuronal apoptosis in MCAO/R
rats. Furthermore, western blot analysis shown that treatment with NX210
up-regulated the expression of Integrin-β1, phosphorylated-PI3K
(p-PI3K) and phosphorylated-Akt (p-Akt). The Integrin-β1 specific
inhibitor, ATN-161, was used to identify pathways involved. The
anti-oxidation activities and anti-apoptosis of NX210 was reversed by
treatment with ATN-161. Overall, our results indicated that NX210
prevents oxidative stress and neuronal apoptosis in cerebral I/R via
upregulation of the Integrin-β1/PI3K/Akt signaling pathway. These
results indicated that NX210 may be a promising therapeutic candidate
for ischemic stroke.
No comments:
Post a Comment